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THE purpose of this study was to evaluate the potential
role of LTB and cysteinyl leukotrienes in Lyme disease
(LD). Therefore, a total number of 34 patients divided into
four groups was studied. The patients were classified as
having Lyme arthritis (n=7) or Lyme meningitis
(n 10), and as control groups patients with a non-
inflammatory arthropathy (NIA) (n 7) and healthy sub-
jects (n 10). LTB as well as LTC secretion from stimu-
lated polymorphonuclear leukocytes (PMNL) from all
groups of patients showed no statistical differences. LTB
levels in synovial fluid were significantly increased in
patients with Lyme arthritis (median 142ng/ml, range
88-296) when compared to the control subjects with NIA
(median 46 ng/ml, range 28-72) (p < 0.05). No statisti-
cal difference of urinary LTE levels between all the
different groups of patients was observed. These results
show that cysteinyl leukotrienes do not play an important
role in the pathogenesis of LD. In contrast to previous
findings in rheumatoid arthritis, LTB4 production from
stimulated PMNL was not found to be increased in LD.
However, the significantly elevated levels of LTB4 in
synovial fluid of patients with Lyme arthritis underline
the involvement of LTB in the pathogenesis of this
disease.
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Introduction
Lyme disease (LD) is a multisystem infection
caused by the spirochete Borrelia burgdorferi which
is transmitted by Ixodes ticks.
1-3 The disease
is associated with a variety of clinical manifestations
which include erythema migrans, lymphocytic
meningitis, motor or sensory radiculitis and,
particularly in later stages, involvement of the joints
in the form of asymmetrical mono- or oligoar-
thritis. 4,5
Cytokines, such as interleukin-1, interleukin-6 or
tumour necrosis factor, have been implicated in the
pathophysiology of LD. 6’7 However, the potential
role of other mediators of inflammation such as
leukotrienes in LD has not received a great deal of
attention. Leukotriene B4 (LTB4) one of the most
powerful chemotactic and chemokinetic agents,
8 has
been found to exert strong leukocytotropic
activities and can cause neutrophil degranulation.
It is readily synthesized by phagocytic cells,
principally neutrophils
1 and macrophages on
challenge with a variety of stimuli. The cysteinyl
leukotrienes (LTC4, LTD4, LTE4), however,
increase microvascular permeability, induce symp-
toms of smooth muscle contraction and cause
oedema.
12-15
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Increased LTB4 production by stimulated poly-
morphonuclear leukocytes (PMNL) from patients
with rheumatoid arthritis as well as elevated LTB4
in synovial tissues in rheumatoid arthritis and
spondyloarthritis has already been demonstra-
ted.
6-8 Elevated urinary LTE4 levels have been
reported in patients with active systemic lupus
erythematosus, a connective tissue disease, char-
acterized by marked immunological abnormalities
leading to inflammation and tissue injury.
19 These
data also suggest an involvement of leukotrienes in
human inflammatory disease such as LD.
The aim of this study was therefore to evaluate
the potential role ofLTB4 and cysteinyl leukotrienes
in patients with Lyme arthritis and Lyme meningitis
in comparison to patients with noninflammatory
arthropathy and healthy subjects. LTB4 as well as
LTC4 production was quantified in stimulated
PMNL; moreover, LTB4 levels were determined in
synovial fluid and additionally LTE4 was measured
in the urine of all patients.
Materials and Methods
Patients: A total of 34 patients was entered into
this study after informed consent was obtained.
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The patients were classified as having either (i)
meningitis due to an infection with B. burgdorferi
with a characteristic immunoblot pattern and
intrathecally produced antibodies (n 10); (ii)
mono- or oligoarthritis serologically positive to B.
burgdorferi by characteristic immunoblot pattern
(n 7); or (iii) patients with a noninflammatory
arthropathy (NIA) such as degenerative or
traumatic joint disease (n 7) as a control group
to Lyme arthritis; and (iv) a healthy control
group (n 10). None of the patients received any
medication before the study and all had a normal
liver and renal function. In all patients other
bacterial, viral or rheumatological diseases could
be excluded.
Serological assaysfor diagnosis ofLyme disease: The indirect
immunofluorescence assay, quantitative enzyme
immunoassay (EIA) and immunoblot were per-
formed as described previously.2’21 Cut-off titres
were 256 (IgG) or 32 (IgM), respectively, for IFA
and 200 standard units (IgG) for EIA. CSF
antibody concentrations were measured by means
of the quantitative EIA using a cut-off value of 2.0
standard units. Diagnosis of LD was established in
each patient by characteristic immunoblot accord-
ing to the criteria described previously.2’22
Quantification of LTB4 and LTC4 in stimulated PMNL:
Heparinized venous blood was obtained from all
patients studied. After removal of mononuclear
cells by Ficoll-Hypaque density gradient centri-
fugation, the neutrophil-rich pellet was sedimented
by dextran. Residual erythrocytes were lysed by
hypotonic saline (0.45%). Purity and viability of the
neutrophil suspension as assessed by Trypan blue
exclusion was consistently more than 95%.
Activation of isolated PMNL with calcium
ionophore A23187 (10 #M; Sigma Chemical Co., St
Louis, MO) was carried out as described.
23
3H-labelled LTB4 or H-labelled LTC4 (both Du
Pont-New England Nuclear, Boston, MA) was
added as an internal standard. Samples were
pumped through activated Sep-Pak C18 cartridges
(Waters, Milford, MA). The cartridges were washed
with distilled water and eluted with 5 ml 90%
aqueous methanol containing 1 mM 4-hydroxy-
2,2,6,6-tetramethylpiperidine-N(1)-oxyl (HTMP;
Sigma Chemicals Co., St Louis, MO) and 0.5 mM
EDTA. The eluates were evaporated to dryness
under reduced pressure and resuspended in 30%
ice-cold aqueous methanol. The samples were then
injected into a C18 reversed-phase high-perfor-
mance liquid chromatography (RP-HPLC) column
(Shandon, Runcorn, UK) and eluted through a
HPLC system (Knauer, Berlin, FRG) at a constant
flow rate of 1 ml/min, using a mixture of
acetonitrile/water (38:62 vol/vol) the aqueous part
containing 0.1% acetic acid, 1 mM EDTA, and
adjusted to pH 5.6 by ammonium hydroxide for
separation of LTB4. LTC4 fractions were prepared
isocratically with a methanol/water (65:35 vol/vol)
system, the aqueous part showing the identical
composition as described above. The fractions
having the same elution time as the synthetic LTB4
or LTC4 were collected and immunoreactive LTB4
as well as LTC4 content was determined by EIA
(Cayman, Ann Arbor, MA).
Measurement of LTB4 in synovial quid: Synovial fluid
was aspirated in all patients with Lyme arthritis and
noninflammatory arthropathy as part of diagnostic
procedures from knee joints and centrifuged at
2000 x g for 10 min to remove cells and
particulate material; the supernatant fluid was
stored at -80C until LTB4 was extracted. After
H-labelled LTB4 was added to each 2-3 ml sample
of synovial fluid, the samples were titrated to pH
4.0 with 2 M citric acid. Each sample was extracted
three times with 4 ml of chloroform:methanol (2:1
vol/vol), the organic phases were pooled and dried
under nitrogen. LTB4 was resolved and purified by
Sep-Pak C18 extraction and RP-HPLC as described
above. Quantification of LTB4 was performed by
EIA as stated above.
Urine LTE4 anasis: Urine was obtained from
spontaneous micturition and mixed with two
volumes of 90% (vol/vol) aqueous methanol of pH
8.5 containing 0.5 mM EDTA, 1 mM HTMP, and
20 mM KHCO, and stored at -80C under argon
until later use. Aliquots of each urine sample were
screened to exclude the presence of pathological
constituents. Urinary LTE4 was measured essenti-
ally as described elsewhere.24 Urine samples
were tested in duplicate. Samples were allowed to
thaw immediately before the assay. H-labelled
LTE4 (Du Pont-New England Nuclear, Boston,
MA) was added as an internal standard. Samples
were then acidified to pH 4.5 by addition of 0.1 M
HC1, homogenized, and pumped through activated
Sep-Pak cartridges as already described. Fractions
having the same elution time as the synthetic LTE4
were separated by RP-HPLC as described above for
LTC4. The immunoreactive LTE4 content was
determined by EIA (Cayman, Ann Arbor, MA).
Statisticalanasis: The Wilcoxon-Mann-Whitney test
for the one-sided problem was used for statistical
comparison between the different groups of
patients. Differences were considered significant
when p was less than 0.05.
Results
LTB4 and LTC4 secretion from stimulated PMNL
LTB4 as well as LTC4 secretion from stimulated
PMNL from all groups of patients is shown in
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Table 1. LTB4 and LTC4 production from stimulated polymorphonuclear leukocytes
from patients with Lyme arthritis, noninflammatory arthropathy (NIA), Lyme meningitis,
and healthy subjects. Values are given as the median with the range in brackets
Leukotriene Lyme N IA Lyme Healthy
(ng per 106 cells) arthritis (n 7) meningitis subjects
(n 7) (n 10) (n 10)
LTB4 40.0 38.4 39.3 35.2
(34.2-47.1) (33.4-44.8) (32.0-45.9) (33.4-44.6)
LTC, 4.8 4.6 5.3 5.0
(4.1-5.6) (4.0-5.3) (4.4-5.8) (3.9-5.5)
Table 1. No statistical difference of LTB4 as well
as LTC4 production between all groups of
patients was observed.
LTB4 in synovial quid: LTB4 was detected in all
synovial fluid samples tested. ,LTB4 levels in
synovial fluid were significantly increased in
patients with Lyme arthritis (median 142 ng/ml,
range 88-296) when compared to the control
subjects with NIA (median 46 ng/ml, range 28-72)
(p < 0.05) (Fig. 1). Although the total white blood
cell counts in synovial fluid were higher in the
patients with Lyme arthritis than in NIA, no
significant correlation was found between the white
blood cell count and the LTB4 levels in synovial
fluid of patients with Lyme arthritis (r 0.14) or
with NIA (r 0.15).
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FIG. 1. LTB4 levels in synovial fluid of patients with Lyme arthritis or
noninflammatory arthropathy (NIA). Values are expressed as mean-I-
S.E.M. *p < 0.05 as compared to patients with NIA.
LTE4 in urine: Urinary LTE4 levels of all patients
are given in pmol/1 as well as in nmol/mol creatinine
(Table 2). No statistical difference of LTE4 levels
between the different groups of patients was
observed.
Discussion
The present data indicate that the synovial levels
of the lipoxygenase product LTB4 is elevated in
Lyme arthritis compared with the levels in synovia
of subjects with NIA (Fig. 1). Similar results of
increased synovial LTB4 levels have been reported
only in rheumatoid arthritis. 17’18 LTB4 is chemotac-
tic for neutrophils and eosinophils in vitro at a
concentration as low as 3 ng/ml and evokes a
maximal chemotactic response at 30 ng/ml.
2s Thus,
the concentration of LTB4 in synovial fluid may be
suflqcient to contribute to the local inflammatory
reaction. Because the involvement of LTB4 in
several T-cell activation stages, namely prolifera-
tion, induction of helper and suppressor function
and production of interleukin-2, interferon-226 and
interleukin-1,
27 LTB4 might contribute to the
pathogenesis of Lyme arthritis.
In contrast to synovial fluid and previous
findings of elevated LTB4 production from PMNL
in rheumatoid arthritis,
16 the LTB4 secretion from
stimulated PMNL was detected at similar levels in
patients with Lyme arthritis, NIA, Lyme meningi-
tis, and healthy controls (Table 1). This demon-
strates that peripheral blood leukocytes do not
produce increased quantities of LTB4 in LD. These
results suggest that local but not systemic
Table 2. LTE in urine of patients with arthritis or meningitis due to an infection
with B. burgdorferi (Lyme disease), noninflammatory arthropathy (NIA) and
healthy subjects. Values are given as the median with the range in brackets
LTE4 Lyme N IA Lyme Healthy
(concentration) arthritis (n 7) meningitis subjects
(n 7) (n 10) (n 10)
pmol/I 279 262 273 265
(89-476) (72-435) (95-465) (70-430)
nmol/mol creatinine 25 20 23 19
18-62 (15-54) 16-56 (11-48)
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production of LTB4 could account for symptoms
of arthritis in late LD.
Although isolation of B. burgdorferi is very
difficult in Lyme arthritis it has been achieved in
some cases from synovial fluid years after onset.
28
Up to now, it is not clear whether autoreactivity as
well as increased synovial LTB4 is an epiphenome-
non of persistent infection or is an important factor
in tissue damage. The mechanisms underlying this
process are a prospect for future research. An exact
knowledge of the role of LTB4 in the pathogenetic
contribution in Lyme arthritis may yield new
therapeutic approaches, e.g. in the (local) applica-
tion of selective inhibitors or antagonists.
The results also show that cysteinyl leukotrienes
are not enhanced when generated in LD. LTC4
production from PMNL in patients with LD did
not differ from those measured in NIA and healthy
subjects (Table 1). Urinary LTE4 has been proposed
and used as the index metabolite for the systemic
generation of cysteinyl leukotrienes in
humans. 19’29-31 Urine LTE4 levels in patients with
Lyme arthritis or Lyme meningitis, however, were
not significantly different from patients with NIA
or healthy controls (Table 2). Recent data indicate
that increased synthesis of leukotrienes as measured
by a rise in urinary LTE4 levels is associated with
active systemic lupus erythematosus and sclero-
derma and suggest that cysteinyl leukotrienes may
mediate certain symptoms associated with these
diseases.
19 It seems possible that elevated LTE4
levels were not seen in our patients with Lyme
arthritis due to the more localized nature of the
inflammatory process. As in rheumatoid arthritis
where LTE4 levels were also found to be normal,
19
most inflammation is localized to the synovium.
In summary, the results show that cysteinyl
leukotrienes do not play an important role in the
pathogenesis of LD. LTB4 production from
stimulated PMNL was not found to be increased in
LD. However, the significantly elevated levels of
LTB4 in synovial fluid in patients with Lyme
arthritis underline the involvement of LTB4 in the
pathogenesis of this disease.
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